Physician profile
Sara Krokos
NPI 1487262226
$1,965.18
in general payments reported to CMS, 2019-2025
18 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.61 · 2022: $285 · 2023: $605 · 2024: $881 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.76 | 2023-2025 | |
| Novo Nordisk INC | $280.66 | 2023-2025 | Wegovy |
| Medtronic, INC. | $201.25 | 2022-2023 | Intellis Adaptivestim |
| Neuronetics, INC. | $193.60 | 2022 | |
| Antares Pharma, INC. | $172.02 | 2024-2025 | Xyosted |
| Lilly USA, LLC | $118.72 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $95.84 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $87.69 | 2023-2024 | Veozah |
| Pfizer INC. | $59.77 | 2023-2024 | |
| Qol Medical, LLC | $48.73 | 2023 | Sucraid |
| Halozyme INC | $39.92 | 2023 | |
| Alexion Pharmaceuticals, INC. | $30.15 | 2024 | Strensiq |
| Daiichi Sankyo INC. | $29.37 | 2024 | Injectafer |
| Axsome Therapeutics, INC. | $23.83 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.46 | 2023 | Xifaxan, Trulance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.80 | 2023 | |
| Hologic Sales and Service, LLC | $18.21 | 2021 | |
| Gilead Sciences, INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Krokos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.